FLT3 and acute myeloid leukemia: These mutations particularly occur in AML without chromosomal abnormalities detected (normal karyotypes) and represent a major issue in the clinical management of patients since they could provide targets for both therapy (i.e., tyrosine kinase inhibitors in FLT3-ITD positive AML) and molecular monitoring of residual disease.